OraSure Technologies Business Model Canvas
Business Model Canvas Preview - Strategic Blueprint for Diagnostics Growth
Unlock the strategic blueprint behind OraSure Technologies with our concise Business Model Canvas preview — see how value propositions, partnerships, and revenue streams connect to drive growth. Dive into market positioning, regulatory advantages, and scaling levers that investors and founders need. Download the full Word/Excel canvas for a section-by-section, actionable roadmap you can use for benchmarking and strategy.
Partnerships
Healthcare providers & clinics
Primary care clinics, sexual health centers and community health organizations deploy OraSure point-of-care tests, driving recurring demand amid an estimated 1.2 million people living with HIV in the US (CDC). Clinical partners supply real-world feedback on usability, sensitivity and workflow integration, supporting pilots and population screening initiatives. Joint education and training programs increase adoption and improve outcomes. Founded 1988, OraSure leverages these networks for product iteration.
Public health agencies & NGOs
Partnerships with CDC-backed programs, ministries of health and NGOs expand access to HIV and infectious disease testing, targeting the estimated 38.4 million people living with HIV globally (UNAIDS 2023). These stakeholders fund screening campaigns and bulk purchases—often covering millions of tests annually—and support inclusion of OraSure assays in national guidelines and reimbursement pathways. Data-sharing feeds national surveillance and WHO reporting, enabling measurement of program impact and test uptake.
Distributors & pharmacy chains
National distributors and retail pharmacy networks (over 20,000 US pharmacy locations across CVS, Walgreens and Walmart) extend OraSure’s OTC and professional channel reach and handle last-mile logistics, shelf space and in-store promotions. Co-marketing agreements and planogram optimization with chains boost sell-through and inventory turnover. Regional distributors enable faster international market penetration across Europe and Latin America.
Regulatory & standards bodies
Collaboration with FDA, EMA/CE and standards groups secures compliant pathways and faster market entry; FDA 510(k) median review was about 89 days in 2024, helping OraSure pace launches. Pre-submission meetings materially de-risk clinical strategy and reduce review cycles. Post-market surveillance frameworks and CLIA-waiver/OTC alignment sustain quality and broaden addressable markets.
- Regulatory partners: FDA, EMA/CE, standards bodies
- 2024 FDA 510(k) median review ~89 days
- Pre-sub meetings reduce review cycles
- CLIA-waiver/OTC alignment expands TAM
Research institutions & OEM partners
Universities, CROs, and biotech partners co-develop assays and validate novel specimen types, giving OraSure access to external expertise and clinical validation channels. OEM and white-label agreements embed OraSure collection kits into broader diagnostic workflows, extending commercial reach through partner sales forces. Research collaborators provide cohorts and datasets while joint IP development accelerates pipeline expansion and technology licensing.
- Co-development with academic/CRO partners
- OEM/white-label distribution
- Access to cohorts and datasets
- Joint IP accelerates pipeline
POC/OTC HIV testing scaled by clinical, retail & NGO partners - 1.2M US, 20,000+ locs
OraSure’s clinical, public-health and retail partners (primary care, sexual-health centers; >20,000 US pharmacy locations) drive recurring POC and OTC demand for assays amid ~1.2M US and 38.4M global people living with HIV (CDC; UNAIDS 2023). Regulatory and NGO linkages (FDA 510(k) median 89 days in 2024) speed market entry and scale screening campaigns. Academic/CRO/OEM collaborations accelerate validation, IP and distribution.
| Partner type | Role | 2024 metric |
|---|---|---|
| Clinical/Community | POC deployment | 1.2M US PLWH |
| Retail/Distrib | OTC reach | 20,000+ US locations |
| Regulatory/NGO | Market access | FDA 510(k) median 89d |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for OraSure Technologies that maps customer segments, channels, value propositions, revenue streams, key partners and activities across the 9 classic blocks; includes competitive advantages, SWOT-linked insights and actionable validation using real company data—ideal for presentations, funding discussions and strategic planning.
Customizable Excel Spreadsheet
High-level view of OraSure Technologies' business model that quickly identifies how diagnostic innovation, partnerships, and distribution address testing access and accuracy gaps—editable and shareable for rapid team alignment and decision-making.
Activities
Assay R&D and validation
Designing, optimizing and clinically validating rapid tests for infectious disease and substance abuse, with analytical and clinical studies commonly involving hundreds to thousands of specimens to support regulatory filings. Iterative improvements target sensitivity >95% and specificity >98% while simplifying use. Pipeline prioritization is data-driven, aligning with epidemiology and customer demand across top pathogen categories.
Manufacturing & quality control
Scaled production of lateral-flow test kits and molecular collection devices is performed under GMP and ISO 13485 standards, with dedicated cleanrooms and validated processes to maintain regulatory compliance.
In-process testing and lot-release controls, including bioburden and functional assays, ensure batch-to-batch consistency and traceability across production runs.
Supply planning models account for seasonality and public-health surges, coordinating raw material vendors and safety stock to prevent disruption.
Continuous improvement initiatives, using lean and Six Sigma tools, target reductions in scrap and cycle times to improve yield and throughput.
Regulatory affairs & compliance
Regulatory affairs manages submissions for CLIA-waived, OTC and professional-use indications globally, supporting OraSure (NASDAQ: OSUR) product portfolio and enabling market access across multiple regions. Continuous post-market surveillance, vigilance reporting and audits adhere to timelines (15-day serious incident reporting in the EU) and internal KPIs, driving corrective actions. Labeling, UDI and QMS maintenance align with IVDR and FDA requirements; regulatory engagement expedites label changes and indication expansions.
Commercial sales & market access
Field sales, distributor enablement, and provider education drive clinical adoption while HEOR evidence underpins reimbursement and guideline inclusion; contracting with GPOs and governments secures volume (GPOs influence ~90% of US hospital purchasing in 2024) and targeted digital marketing expands OTC awareness and e‑commerce reach.
- Field sales
- Distributor enablement
- Healthcare education
- HEOR → reimbursement/guidelines
- GPOs/government contracts (~90% hospital reach)
- Digital marketing → OTC growth
Supply chain & vendor management
OraSure sources membranes, reagents, plastics and packaging from qualified suppliers with dual-sourcing covering ~80% of critical components and safety stocks typically sized at 45–60 days to ensure supply continuity.
Cold-chain and hazardous-material logistics are coordinated through certified carriers and temperature-monitored lanes, while continuous cost and lead-time optimization efforts target ~20% lead-time reduction and ~200 bps gross-margin improvement.
- Dual-sourcing ~80% of critical parts
- Safety stocks 45–60 days
- 20% lead-time reduction target
- ~200 bps gross-margin uplift goal
GMP/ISO 13485 rapid diagnostics: 80% dual-sourcing, 90% GPO reach
Design, GMP/ISO 13485 manufacture and clinical validation of rapid diagnostics; QA/lot-release, global regulatory submissions and post-market vigilance (15-day EU SI reporting), supply planning with dual-sourcing ~80% and 45–60 days safety stock, sales/distribution via GPOs (~90% hospital reach), CI targets: −20% lead-time, ~200 bps gross-margin uplift.
| Metric | 2024 |
|---|---|
| Dual-sourcing | ~80% |
| Safety stock | 45–60 days |
| GPO reach | ~90% |
| CI targets | −20% LT / ~200 bps |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual OraSure Technologies Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—fully formatted and complete—in editable Word and Excel versions. No surprises, ready to present and use immediately.
Business Model Canvas Preview - Strategic Blueprint for Diagnostics Growth
Unlock the strategic blueprint behind OraSure Technologies with our concise Business Model Canvas preview — see how value propositions, partnerships, and revenue streams connect to drive growth. Dive into market positioning, regulatory advantages, and scaling levers that investors and founders need. Download the full Word/Excel canvas for a section-by-section, actionable roadmap you can use for benchmarking and strategy.
Partnerships
Healthcare providers & clinics
Primary care clinics, sexual health centers and community health organizations deploy OraSure point-of-care tests, driving recurring demand amid an estimated 1.2 million people living with HIV in the US (CDC). Clinical partners supply real-world feedback on usability, sensitivity and workflow integration, supporting pilots and population screening initiatives. Joint education and training programs increase adoption and improve outcomes. Founded 1988, OraSure leverages these networks for product iteration.
Public health agencies & NGOs
Partnerships with CDC-backed programs, ministries of health and NGOs expand access to HIV and infectious disease testing, targeting the estimated 38.4 million people living with HIV globally (UNAIDS 2023). These stakeholders fund screening campaigns and bulk purchases—often covering millions of tests annually—and support inclusion of OraSure assays in national guidelines and reimbursement pathways. Data-sharing feeds national surveillance and WHO reporting, enabling measurement of program impact and test uptake.
Distributors & pharmacy chains
National distributors and retail pharmacy networks (over 20,000 US pharmacy locations across CVS, Walgreens and Walmart) extend OraSure’s OTC and professional channel reach and handle last-mile logistics, shelf space and in-store promotions. Co-marketing agreements and planogram optimization with chains boost sell-through and inventory turnover. Regional distributors enable faster international market penetration across Europe and Latin America.
Regulatory & standards bodies
Collaboration with FDA, EMA/CE and standards groups secures compliant pathways and faster market entry; FDA 510(k) median review was about 89 days in 2024, helping OraSure pace launches. Pre-submission meetings materially de-risk clinical strategy and reduce review cycles. Post-market surveillance frameworks and CLIA-waiver/OTC alignment sustain quality and broaden addressable markets.
- Regulatory partners: FDA, EMA/CE, standards bodies
- 2024 FDA 510(k) median review ~89 days
- Pre-sub meetings reduce review cycles
- CLIA-waiver/OTC alignment expands TAM
Research institutions & OEM partners
Universities, CROs, and biotech partners co-develop assays and validate novel specimen types, giving OraSure access to external expertise and clinical validation channels. OEM and white-label agreements embed OraSure collection kits into broader diagnostic workflows, extending commercial reach through partner sales forces. Research collaborators provide cohorts and datasets while joint IP development accelerates pipeline expansion and technology licensing.
- Co-development with academic/CRO partners
- OEM/white-label distribution
- Access to cohorts and datasets
- Joint IP accelerates pipeline
POC/OTC HIV testing scaled by clinical, retail & NGO partners - 1.2M US, 20,000+ locs
OraSure’s clinical, public-health and retail partners (primary care, sexual-health centers; >20,000 US pharmacy locations) drive recurring POC and OTC demand for assays amid ~1.2M US and 38.4M global people living with HIV (CDC; UNAIDS 2023). Regulatory and NGO linkages (FDA 510(k) median 89 days in 2024) speed market entry and scale screening campaigns. Academic/CRO/OEM collaborations accelerate validation, IP and distribution.
| Partner type | Role | 2024 metric |
|---|---|---|
| Clinical/Community | POC deployment | 1.2M US PLWH |
| Retail/Distrib | OTC reach | 20,000+ US locations |
| Regulatory/NGO | Market access | FDA 510(k) median 89d |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for OraSure Technologies that maps customer segments, channels, value propositions, revenue streams, key partners and activities across the 9 classic blocks; includes competitive advantages, SWOT-linked insights and actionable validation using real company data—ideal for presentations, funding discussions and strategic planning.
Customizable Excel Spreadsheet
High-level view of OraSure Technologies' business model that quickly identifies how diagnostic innovation, partnerships, and distribution address testing access and accuracy gaps—editable and shareable for rapid team alignment and decision-making.
Activities
Assay R&D and validation
Designing, optimizing and clinically validating rapid tests for infectious disease and substance abuse, with analytical and clinical studies commonly involving hundreds to thousands of specimens to support regulatory filings. Iterative improvements target sensitivity >95% and specificity >98% while simplifying use. Pipeline prioritization is data-driven, aligning with epidemiology and customer demand across top pathogen categories.
Manufacturing & quality control
Scaled production of lateral-flow test kits and molecular collection devices is performed under GMP and ISO 13485 standards, with dedicated cleanrooms and validated processes to maintain regulatory compliance.
In-process testing and lot-release controls, including bioburden and functional assays, ensure batch-to-batch consistency and traceability across production runs.
Supply planning models account for seasonality and public-health surges, coordinating raw material vendors and safety stock to prevent disruption.
Continuous improvement initiatives, using lean and Six Sigma tools, target reductions in scrap and cycle times to improve yield and throughput.
Regulatory affairs & compliance
Regulatory affairs manages submissions for CLIA-waived, OTC and professional-use indications globally, supporting OraSure (NASDAQ: OSUR) product portfolio and enabling market access across multiple regions. Continuous post-market surveillance, vigilance reporting and audits adhere to timelines (15-day serious incident reporting in the EU) and internal KPIs, driving corrective actions. Labeling, UDI and QMS maintenance align with IVDR and FDA requirements; regulatory engagement expedites label changes and indication expansions.
Commercial sales & market access
Field sales, distributor enablement, and provider education drive clinical adoption while HEOR evidence underpins reimbursement and guideline inclusion; contracting with GPOs and governments secures volume (GPOs influence ~90% of US hospital purchasing in 2024) and targeted digital marketing expands OTC awareness and e‑commerce reach.
- Field sales
- Distributor enablement
- Healthcare education
- HEOR → reimbursement/guidelines
- GPOs/government contracts (~90% hospital reach)
- Digital marketing → OTC growth
Supply chain & vendor management
OraSure sources membranes, reagents, plastics and packaging from qualified suppliers with dual-sourcing covering ~80% of critical components and safety stocks typically sized at 45–60 days to ensure supply continuity.
Cold-chain and hazardous-material logistics are coordinated through certified carriers and temperature-monitored lanes, while continuous cost and lead-time optimization efforts target ~20% lead-time reduction and ~200 bps gross-margin improvement.
- Dual-sourcing ~80% of critical parts
- Safety stocks 45–60 days
- 20% lead-time reduction target
- ~200 bps gross-margin uplift goal
GMP/ISO 13485 rapid diagnostics: 80% dual-sourcing, 90% GPO reach
Design, GMP/ISO 13485 manufacture and clinical validation of rapid diagnostics; QA/lot-release, global regulatory submissions and post-market vigilance (15-day EU SI reporting), supply planning with dual-sourcing ~80% and 45–60 days safety stock, sales/distribution via GPOs (~90% hospital reach), CI targets: −20% lead-time, ~200 bps gross-margin uplift.
| Metric | 2024 |
|---|---|
| Dual-sourcing | ~80% |
| Safety stock | 45–60 days |
| GPO reach | ~90% |
| CI targets | −20% LT / ~200 bps |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual OraSure Technologies Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—fully formatted and complete—in editable Word and Excel versions. No surprises, ready to present and use immediately.
Original: $10.00
-65%$10.00
$3.50Description
Business Model Canvas Preview - Strategic Blueprint for Diagnostics Growth
Unlock the strategic blueprint behind OraSure Technologies with our concise Business Model Canvas preview — see how value propositions, partnerships, and revenue streams connect to drive growth. Dive into market positioning, regulatory advantages, and scaling levers that investors and founders need. Download the full Word/Excel canvas for a section-by-section, actionable roadmap you can use for benchmarking and strategy.
Partnerships
Healthcare providers & clinics
Primary care clinics, sexual health centers and community health organizations deploy OraSure point-of-care tests, driving recurring demand amid an estimated 1.2 million people living with HIV in the US (CDC). Clinical partners supply real-world feedback on usability, sensitivity and workflow integration, supporting pilots and population screening initiatives. Joint education and training programs increase adoption and improve outcomes. Founded 1988, OraSure leverages these networks for product iteration.
Public health agencies & NGOs
Partnerships with CDC-backed programs, ministries of health and NGOs expand access to HIV and infectious disease testing, targeting the estimated 38.4 million people living with HIV globally (UNAIDS 2023). These stakeholders fund screening campaigns and bulk purchases—often covering millions of tests annually—and support inclusion of OraSure assays in national guidelines and reimbursement pathways. Data-sharing feeds national surveillance and WHO reporting, enabling measurement of program impact and test uptake.
Distributors & pharmacy chains
National distributors and retail pharmacy networks (over 20,000 US pharmacy locations across CVS, Walgreens and Walmart) extend OraSure’s OTC and professional channel reach and handle last-mile logistics, shelf space and in-store promotions. Co-marketing agreements and planogram optimization with chains boost sell-through and inventory turnover. Regional distributors enable faster international market penetration across Europe and Latin America.
Regulatory & standards bodies
Collaboration with FDA, EMA/CE and standards groups secures compliant pathways and faster market entry; FDA 510(k) median review was about 89 days in 2024, helping OraSure pace launches. Pre-submission meetings materially de-risk clinical strategy and reduce review cycles. Post-market surveillance frameworks and CLIA-waiver/OTC alignment sustain quality and broaden addressable markets.
- Regulatory partners: FDA, EMA/CE, standards bodies
- 2024 FDA 510(k) median review ~89 days
- Pre-sub meetings reduce review cycles
- CLIA-waiver/OTC alignment expands TAM
Research institutions & OEM partners
Universities, CROs, and biotech partners co-develop assays and validate novel specimen types, giving OraSure access to external expertise and clinical validation channels. OEM and white-label agreements embed OraSure collection kits into broader diagnostic workflows, extending commercial reach through partner sales forces. Research collaborators provide cohorts and datasets while joint IP development accelerates pipeline expansion and technology licensing.
- Co-development with academic/CRO partners
- OEM/white-label distribution
- Access to cohorts and datasets
- Joint IP accelerates pipeline
POC/OTC HIV testing scaled by clinical, retail & NGO partners - 1.2M US, 20,000+ locs
OraSure’s clinical, public-health and retail partners (primary care, sexual-health centers; >20,000 US pharmacy locations) drive recurring POC and OTC demand for assays amid ~1.2M US and 38.4M global people living with HIV (CDC; UNAIDS 2023). Regulatory and NGO linkages (FDA 510(k) median 89 days in 2024) speed market entry and scale screening campaigns. Academic/CRO/OEM collaborations accelerate validation, IP and distribution.
| Partner type | Role | 2024 metric |
|---|---|---|
| Clinical/Community | POC deployment | 1.2M US PLWH |
| Retail/Distrib | OTC reach | 20,000+ US locations |
| Regulatory/NGO | Market access | FDA 510(k) median 89d |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for OraSure Technologies that maps customer segments, channels, value propositions, revenue streams, key partners and activities across the 9 classic blocks; includes competitive advantages, SWOT-linked insights and actionable validation using real company data—ideal for presentations, funding discussions and strategic planning.
Customizable Excel Spreadsheet
High-level view of OraSure Technologies' business model that quickly identifies how diagnostic innovation, partnerships, and distribution address testing access and accuracy gaps—editable and shareable for rapid team alignment and decision-making.
Activities
Assay R&D and validation
Designing, optimizing and clinically validating rapid tests for infectious disease and substance abuse, with analytical and clinical studies commonly involving hundreds to thousands of specimens to support regulatory filings. Iterative improvements target sensitivity >95% and specificity >98% while simplifying use. Pipeline prioritization is data-driven, aligning with epidemiology and customer demand across top pathogen categories.
Manufacturing & quality control
Scaled production of lateral-flow test kits and molecular collection devices is performed under GMP and ISO 13485 standards, with dedicated cleanrooms and validated processes to maintain regulatory compliance.
In-process testing and lot-release controls, including bioburden and functional assays, ensure batch-to-batch consistency and traceability across production runs.
Supply planning models account for seasonality and public-health surges, coordinating raw material vendors and safety stock to prevent disruption.
Continuous improvement initiatives, using lean and Six Sigma tools, target reductions in scrap and cycle times to improve yield and throughput.
Regulatory affairs & compliance
Regulatory affairs manages submissions for CLIA-waived, OTC and professional-use indications globally, supporting OraSure (NASDAQ: OSUR) product portfolio and enabling market access across multiple regions. Continuous post-market surveillance, vigilance reporting and audits adhere to timelines (15-day serious incident reporting in the EU) and internal KPIs, driving corrective actions. Labeling, UDI and QMS maintenance align with IVDR and FDA requirements; regulatory engagement expedites label changes and indication expansions.
Commercial sales & market access
Field sales, distributor enablement, and provider education drive clinical adoption while HEOR evidence underpins reimbursement and guideline inclusion; contracting with GPOs and governments secures volume (GPOs influence ~90% of US hospital purchasing in 2024) and targeted digital marketing expands OTC awareness and e‑commerce reach.
- Field sales
- Distributor enablement
- Healthcare education
- HEOR → reimbursement/guidelines
- GPOs/government contracts (~90% hospital reach)
- Digital marketing → OTC growth
Supply chain & vendor management
OraSure sources membranes, reagents, plastics and packaging from qualified suppliers with dual-sourcing covering ~80% of critical components and safety stocks typically sized at 45–60 days to ensure supply continuity.
Cold-chain and hazardous-material logistics are coordinated through certified carriers and temperature-monitored lanes, while continuous cost and lead-time optimization efforts target ~20% lead-time reduction and ~200 bps gross-margin improvement.
- Dual-sourcing ~80% of critical parts
- Safety stocks 45–60 days
- 20% lead-time reduction target
- ~200 bps gross-margin uplift goal
GMP/ISO 13485 rapid diagnostics: 80% dual-sourcing, 90% GPO reach
Design, GMP/ISO 13485 manufacture and clinical validation of rapid diagnostics; QA/lot-release, global regulatory submissions and post-market vigilance (15-day EU SI reporting), supply planning with dual-sourcing ~80% and 45–60 days safety stock, sales/distribution via GPOs (~90% hospital reach), CI targets: −20% lead-time, ~200 bps gross-margin uplift.
| Metric | 2024 |
|---|---|
| Dual-sourcing | ~80% |
| Safety stock | 45–60 days |
| GPO reach | ~90% |
| CI targets | −20% LT / ~200 bps |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual OraSure Technologies Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive this exact file—fully formatted and complete—in editable Word and Excel versions. No surprises, ready to present and use immediately.
